Tag: Numinus - Psilocybin Alpha

New: Psychedelics 2021: A Year in Review

Numinus Wellness Inc. Reports Q1 2022 Results

Post published:January 20, 2022
Post category:Press Release

Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial

Post published:January 19, 2022
Post category:Press Release

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Post published:January 14, 2022
Post category:Press Release

Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

Post published:December 22, 2021
Post category:Press Release

Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021

Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021

Post published:December 14, 2021
Post category:Press Release

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Post published:December 9, 2021
Post category:Press Release

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Post published:November 29, 2021
Post category:Press Release

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Post published:November 26, 2021
Post category:Press Release

Numinus Announces Departure of Stacey Wallin

Numinus Announces Departure of Stacey Wallin

Post published:November 25, 2021
Post category:Press Release

Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021

Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021

Post published:November 22, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.